Early detection of Alzheimer's disease using PiB and FDG PET

Neurobiology of Disease

Volumn 72, Issue Part A, 2014, Pages 117-122

  Cohen, Ann D ^a   Klunk, William E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid; FDG; Glucose metabolism; Neuroimaging; Pittsburgh compound B

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE; PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; AMYLOID BETA PROTEIN; ANILINE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; THIAZOLE DERIVATIVE;

ALZHEIMER DISEASE; BRAIN REGION; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; GLUCOSE METABOLISM; HUMAN; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN LOCALIZATION; REVIEW; BRAIN; COGNITION; METABOLISM; MILD COGNITIVE IMPAIRMENT; PATHOLOGY; PHYSIOLOGY; SCINTISCANNING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOMARKERS; BRAIN; COGNITION; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES;

EID: 84909645342     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.05.001     Document Type: Review

References (95)

1. Aizenstein H.J., et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 2008, 65:1509-1517.
2. Albert M.S., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
3. Anchisi D., et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch. Neurol. 2005, 62:1728-1733.
4. Archer H.A., et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann. Neurol. 2006, 60:145-147.
5. Arnaiz E., et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001, 12:851-855.
6. Braak H., Braak E. Alzheimer's disease: striatal amyloid deposits and neurofibrillary changes. J. Neuropathol. Exp. Neurol. 1990, 49:215-224.
7. Brilliant M.J., et al. The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer's disease. Neuropathol. Appl. Neurobiol. 1997, 23:322-325.
8. Brody D.L., et al. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 2008, 321:1221-1224.
9. Buckner R.L., et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 2005, 25:7709-7717.
10. Busse A., et al. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006, 67:2176-2185.
11. Chetelat G., Baron J.C. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage 2003, 18:525-541.
12. Chetelat G., et al. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 2003, 60:1374-1377.
13. Cirrito J.R., et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005, 48:913-922.
14. Cohen A.D., et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J. Neurosci. Off. J. Soc. Neurosci. 2009, 29:14770-14778.
15. de Leon M.J., et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10966-10971.
16. DeKosky S.T., et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 2002, 51:145-155.
17. Del Sole A., et al. Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: an FDG PET study. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:1357-1366.
18. Drzezga A., et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J. Nucl. Med. 2005, 46:1625-1632.
19. Edison P., et al. Amyloid, hypometabolism, and cognition in Alzheimer disease. An [11C]PIB and [18F]FDG PET study. Neurology 2006, 68:501-508.
20. Fagan A.M., et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans. Ann. Neurol. 2006, 59:512-519.
21. Fagan A.M., et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 2007, 64:343-349.
22. Forsberg A., et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 2007, 10.1016/j.neurobiolaging.2007.03.029.
23. Foster N.L., et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007, 130:2616-2635.
24. Friedland R.P., et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J. Comput. Assist. Tomogr. 1983, 7:590-598.
25. Garibotto V., et al. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology 2008, 71:1342-1349.
26. Gauthier S., et al. Mild cognitive impairment. Lancet 2006, 367:1262-1270.
27. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 1991, 12:383-388.
28. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
29. Hardy J., et al. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat. Neurosci. 1998, 1:355-358.
30. Herholz K., et al. Positron emission tomography imaging in dementia. Br. J. Radiol. 2007, 80:S160-S167.
31. Ikonomovic M.D., et al. Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease. Arch. Neurol. 2007, 64:1312-1317.
32. Jack C.R., et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131:665-680.
33. Jack C.R., et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease 2009, vol. 132:1355-1365.
34. Jack C.R., et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann. Neurol. 2012, 71:765-775.
35. Jagust W.J., Mormino E.C. Lifespan brain activity, beta-amyloid, and Alzheimer's disease. Trends Cogn. Sci. 2011, 15:520-526.
36. Jagust W., et al. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann. Neurol. 2006, 59:673-681.
37. Jagust W., et al. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology 2007, 69:871-877.
38. Johnson S.C., et al. Amyloid burden and neural function in people at risk for Alzheimer's Disease. Neurobiol. Aging 2014, 35:576-584.
39. Kantarci K., et al. APOE modifies the association between Abeta load and cognition in cognitively normal older adults. Neurology 2012, 78:232-240.
40. Kemppainen N.M., et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006, 67:1575-1580.
41. Klunk W.E., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
42. Knopman D.S., et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012, 78:1576-1582.
43. Knopman D.S., et al. Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Ann. Neurol. 2012, 73(4):472-480.
44. Knopman D.S., et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with beta-amyloidosis. JAMA Neurol. 2013, 70:1030-1038.
45. Koivunen J., et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011, 76:1085-1090.
46. Landau S.M., et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 2012, 72:578-586.
47. Li Y., et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2169-2181.
48. Lopresti B.J., et al. Simplified Quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J. Nucl. Med. 2005, 46:1959-1972.
49. Lowe V.J., et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J. Nucl. Med. 2009, 50:878-886.
50. McKiernan K.A., et al. A parametric manipulation of factors affecting task-induced deactivation in functional neuroimaging 2003, vol. 15:394-408.
51. Mevel K., et al. Detecting hippocampal hypometabolism in mild cognitive impairment using automatic voxel-based approaches. Neuroimage 2007, 37:18-25.
52. Minoshima S. Imaging Alzheimer's disease: clinical applications. Neuroimaging Clin. N. Am. 2003, 13:769-780.
53. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
54. Mirra S.S., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
55. Mormino E.C., et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
56. Mormino E.C., et al. Relationships between beta-amyloid and functional connectivity in different components of the default mode network in aging. Cereb. Cortex 2011, 21:2399-2407.
57. Morris J.C., et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 2010, 67:122-131.
58. Mosconi L., et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004, 63:2332-2340.
59. Mosconi L., et al. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur. J. Nucl. Med. Mol. Imaging 2006, 33:210-221.
60. Mosconi L., et al. (18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease. J. Nucl. Med. 2007, 48:1129-1134.
61. Mosconi L., et al. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann. N. Y. Acad. Sci. 2008, 1147:180-195.
62. Mosconi L., et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J. Nucl. Med. 2008, 49:390-398.
63. Mosconi L., et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 2009, 72:513-520.
64. Mosconi L., et al. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol. Aging 2013, 34:22-34.
65. Mosconi L., et al. Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD. Neurology 2014, 82(9):752-760.
66. Nebes R.D., et al. Cognitive aging in persons with minimal amyloid-beta and white matter hyperintensities. Neuropsychologia 2013, 51:2202-2209.
67. Nelissen N., et al. Abeta amyloid deposition in the language system and how the brain responds. Brain 2007, 130:2055-2069.
68. Ng S., et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J. Nucl. Med. 2007, 48:547-552.
69. Oh H., et al. Covarying alterations in Abeta deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum. Brain Mapp. 2014, 35:297-308.
70. Perneczky R., et al. Cerebral metabolic correlates of the clinical dementia rating scale in mild cognitive impairment. J. Geriatr. Psychiatry Neurol. 2007, 20:84-88.
71. Pike K.E., et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130:2837-2844.
72. Price J.C., et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J. Cereb. Blood Flow Metab. 2005, 25:1528-1547.
73. Price J.C., et al. FDG and PIBPET imaging in Alzheimer's disease and mild cognitive impairment. Neuropsychopharmacology 2005, 30. (S225-S225).
74. Rabinovici G.D., et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011, 77:2034-2042.
75. Reiman E.M., et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 1996, 96:752-758.
76. 2burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease 2009, vol. 106:6820-6825.
77. Resnick S.M., Sojkova J. Amyloid imaging and memory change for prediction of cognitive impairment. Alzheimers Res. Ther. 2011, 3:3.
78. Rowe C.C., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
79. Rowe C.C., et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 2010, 31:1275-1283.
80. Shulman G.L., et al. Right TPJ deactivation during visual search: functional significance and support for a filter hypothesis. Cereb. Cortex 2007, 17:2625-2633.
81. Silverman D.H., Alavi A. PET imaging in the assessment of normal and impaired cognitive function. Radiol. Clin. N. Am. 2005, 43:67-77. (x).
82. Small G.W., et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6037-6042.
83. Sperling R.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
84. Storandt M., et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch. Neurol. 2009, 66:1476-1481.
85. Suenaga T., et al. Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer's disease. Acta Neuropathol. 1990, 80:280-286.
86. Thal D.R., et al. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
87. Villemagne V.L., et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann. Neurol. 2011, 69:181-192.
88. Villemagne V.L., et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013, 12:357-367.
89. Villemagne V.L., et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2014, (in press). 10.1016/j.neuropsychologia.2008.02.008.
90. Wirth M., et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol. 2013, 70:1512-1519.
91. Wolf D.S., et al. Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. Alzheimer Dis. Assoc. Disord. 1999, 13:226-231.
92. Wolk D.A., et al. Amyloid imaging in mild cognitive impairment subtypes. Ann. Neurol. 2009, 65:557-568.
93. Yi D., et al. Beta-amyloid associated differential effects of APOE epsilon4 on brain metabolism in cognitively normal elderly. Am. J. Geriatr. Psychiatry 2014.
94. Yuan Y., et al. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am. J. Neuroradiol. 2008, 30(2):404-410.
95. Ziolko S.K., et al. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage 2006, 33:94-102.